Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.57 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.53 |
| ▸ | CLK1 | P49759 | 3/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 5/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30380023 | 1.00 | BACE1 (0.57) | BACE1PABPC1CLK1CSNK1DCSNK1E | |
| SCHEMBL46742 | 0.84 | BACE1 (0.55) | BACE1PABPC1CLK1CSNK1DCSNK1E | |
| SCHEMBL29699229 | 0.84 | BACE1 (0.55) | BACE1PABPC1CLK1CSNK1DCSNK1E | |
| SCHEMBL24150165 | 0.79 | HTT (0.58) | CLK1CSNK1DCSNK1EDYRK1AHTT | |
| SCHEMBL557993 | 0.76 | CSNK1D (0.47) | BACE1CLK1CSNK1DCSNK1EDYRK1A | |
| SCHEMBL22449721 | 0.76 | CYP1A2 (0.50) | BACE1CLK1CSNK1DCSNK1EDYRK1A | |
| SCHEMBL31271736 | 0.76 | BACE1 (0.47) | BACE1PABPC1DYRK1ACYP1A2CYP2C19 | |
| SCHEMBL4297504 | 0.76 | BACE1 (0.47) | BACE1PABPC1CLK1DYRK1ACYP1A2 | |
| SCHEMBL25052261 | 0.76 | CLK1 (0.47) | CLK1CSNK1DCSNK1EDYRK1AHTT | |
| SCHEMBL1633846 | 0.76 | BACE1 (0.47) | BACE1PABPC1DYRK1ACYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105924385-A | Diarylthiourea compound with antitumor activity, and preparation method and application thereof | 西安交通大学 | 2016-09-07 | — | — | CN | claimed |
| CN-105924403-A | Cyclomalonamide compound with antitumor activity, and preparation method and application thereof | 西安交通大学 | 2016-09-07 | — | — | CN | claimed |
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| CN-112979615-B | Quinazoline urea compound, preparation method thereof, preparation intermediate, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-11958833-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-16 | — | — | US | disclosed |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230406864-A1 | 7-AZOLE SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230399341-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | MERCK SHARP & DOHME LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399341-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | MERCK SHARP & DOHME LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399341-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | MERCK SHARP & DOHME LLC (US) | 2023-12-14 | — | — | US | disclosed |
| CN-117157297-A | PRMT5 inhibitors | 上海齐鲁制药研究中心有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1981884-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | Amgen, Inc (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| EP-1463505-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Abbott Laboratories (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | BACE1 4366/4885PABPC1 2779/4885CLK1 2881/4885 |
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | BACE1 4000/4885PABPC1 777/4885CLK1 376/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | BACE1 4000/4885PABPC1 777/4885CLK1 376/4885 |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | BACE1 4301/4885PABPC1 650/4885CLK1 1366/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | BACE1 2314/4885PABPC1 2995/4885CLK1 1659/4885 |
| US-20230399341-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | PHKG1, PDXK, HIPK1 | BACE1 4691/4885PABPC1 1313/4885CLK1 86/4885 |
| US-11958833-B2 | Compounds | USP30, USP20, USP10 | BACE1 1219/4885PABPC1 2757/4885CLK1 3882/4885 |
| US-20230406864-A1 | 7-AZOLE SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | PHKG1, HIPK1, PDXK | BACE1 4786/4885PABPC1 1673/4885CLK1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.